- Home
- SER vs DXR Comparison
SER vs DXR Comparison
Compare SER & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- DXR
- Stock Information
- Founded
- SER 2017
- DXR 1970
- Country
- SER United States
- DXR United States
- Employees
- SER N/A
- DXR N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- SER Health Care
- DXR Health Care
- Exchange
- SER Nasdaq
- DXR Nasdaq
- Market Cap
- SER 42.0M
- DXR 46.9M
- IPO Year
- SER 2018
- DXR N/A
- Fundamental
- Price
- SER $3.88
- DXR $13.31
- Analyst Decision
- SER Strong Buy
- DXR Strong Buy
- Analyst Count
- SER 2
- DXR 1
- Target Price
- SER $13.00
- DXR $25.00
- AVG Volume (30 Days)
- SER 20.8K
- DXR 6.4K
- Earning Date
- SER 11-13-2025
- DXR 01-01-0001
- Dividend Yield
- SER N/A
- DXR N/A
- EPS Growth
- SER N/A
- DXR 3.46
- EPS
- SER N/A
- DXR 0.36
- Revenue
- SER $116,000.00
- DXR $66,306.00
- Revenue This Year
- SER $134.46
- DXR N/A
- Revenue Next Year
- SER N/A
- DXR N/A
- P/E Ratio
- SER N/A
- DXR $36.59
- Revenue Growth
- SER N/A
- DXR N/A
- 52 Week Low
- SER $3.70
- DXR $6.55
- 52 Week High
- SER $7.92
- DXR $14.15
- Technical
- Relative Strength Index (RSI)
- SER 39.43
- DXR 53.46
- Support Level
- SER $3.73
- DXR $12.52
- Resistance Level
- SER $4.12
- DXR $14.15
- Average True Range (ATR)
- SER 0.31
- DXR 0.50
- MACD
- SER -0.01
- DXR -0.03
- Stochastic Oscillator
- SER 23.99
- DXR 63.61
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.